Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/30/26
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and WalesGlobeNewsWire • 07/30/26
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to BuyZacks Investment Research • 07/15/26
Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a BetZacks Investment Research • 07/15/26
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?Zacks Investment Research • 07/10/26
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026GlobeNewsWire • 07/07/26
Entertainment Stocks Madison Square Garden, Sphere Rally To New HighsInvestors Business Daily • 06/26/26
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree24/7 Wall Street • 06/25/26
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Cytokinetics Announces Call for Proposals for Annual Corporate Giving ProgramGlobeNewsWire • 06/08/26
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in GermanyGlobeNewsWire • 06/01/26
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha • 05/27/26